LeonaBio Inc

LeonaBio maintains a strong liquidity position, with a current ratio of 3.97 and cash and equivalents of $73.8 million, which significantly exceeds its total liabilities of $27.9 million. The company has no long-term debt, and its debt-to-equity ratio is 0.0, indicating a conservative capital structure. However, the company has negative operating and free cash flows, with operating cash flow of -$48.1 million and free cash flow of -$26.6 million, suggesting ongoing operational cash burn.

Profitability metrics are negative, with a return on equity (ROE) of -32.23% and a return on assets (ROA) of -24.14%, both well below the industry median for biotechnology firms. The company reported a net loss of $26.86 million and an operating loss of $28.03 million, reflecting the high costs associated with R&D and commercialization in the diagnostics space.

Geographically, LeonaBio's revenue is not disclosed by region, but the company's operations are primarily based in the United States. The company has not disclosed segment-level revenue, but its business is concentrated in the development and sale of diagnostic tests, particularly for infectious diseases.

The company's growth trajectory is uncertain, with no disclosed revenue history and no clear guidance on future revenue. Analysts have assigned a mean price target of $16.00, which is 45.45% above the current market price of $11.00, but the mean recommendation is 2.00 (a "buy" rating), with no strong buy ratings.

Risk factors include the company's reliance on a limited product portfolio and the high costs of R&D in the biotechnology sector. The risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. However, the company's negative cash flows and lack of profitability could lead to future dilution if additional capital is required.

Recent events include the continued development of its diagnostic platform, with no major regulatory or legal issues reported. The company has not disclosed any recent acquisitions or strategic partnerships, and its focus remains on expanding its product offerings in the infectious disease diagnostics market.

Leonabio Inc (LONA.O) has recorded a notable addition to its shareholder base, marking a significant development for the company. This change was detected on June 20, 2026, and represents the first analysis for this ticker, meaning there is no prior basis for computing deltas in other metrics. The emergence of this new holder activity provides the initial data point for tracking investor interest in the stock. The specific change involves an investor, identified by ID 465, acquiring a position in Leonabio. As of December 31, 2025, this investor held 153,789 shares. The total value of this holding was approximately $1.16 million USD. This acquisition represents a weight of roughly 0.0017% of the relevant portfolio or index context associated with the investor. This new holding contributes to Leonabio's current ownership structure, which includes a total of seven top holders. The company is currently led by a single officer and has no analyst coverage or index memberships recorded in the available data. The addition of this investor adds to the diversity of the shareholder base, although the overall number of top holders remains limited. The significance of this event lies in its role as the baseline for future monitoring of Leonabio's investor relations. With no prior material changes or cross-source signals available, this holder addition serves as the primary indicator of recent market activity. Investors and analysts will likely watch for subsequent changes in this position or the entry of additional holders to gauge broader market sentiment toward the company.

Operating income −80,5% YoY; Net income −260,4% YoY.

• ▍Operating income −80,5% YoY
• ▍Net income −260,4% YoY
• ▍Free cash flow −267,6% YoY

Operating income −404,7% YoY; Net income −452,5% YoY.

• ▍Operating income −404,7% YoY
• ▍Net income −452,5% YoY
• ▍Free cash flow −459,7% YoY

Operating income +76,8% YoY; Net income +77,0% YoY.

• ▍Operating income +76,8% YoY
• ▍Net income +77,0% YoY
• ▍Free cash flow +77,7% YoY

Operating income +74,0% YoY; Net income +74,1% YoY.

• ▍Operating income +74,0% YoY
• ▍Net income +74,1% YoY
• ▍Free cash flow +74,8% YoY

Operating income -$15.6M.

• ▍Operating income -$15.6M

Operating income -$29.6M.

• ▍Operating income -$29.6M

Operating income -$28.0M.

• ▍Operating income -$28.0M

Operating income −1,4% YoY; Net income −8,9% YoY.

• ▍Operating income −1,4% YoY
• ▍Net income −8,9% YoY
• ▍Free cash flow −9,0% YoY

Operating income +19,6% YoY; Net income +17,6% YoY.

• ▍Operating income +19,6% YoY
• ▍Net income +17,6% YoY
• ▍Free cash flow +17,9% YoY

Operating income −20,6% YoY; Net income −23,0% YoY.

• ▍Operating income −20,6% YoY
• ▍Net income −23,0% YoY
• ▍Free cash flow −22,0% YoY

Operating income −62,5% YoY; Net income −74,4% YoY.

• ▍Operating income −62,5% YoY
• ▍Net income −74,4% YoY
• ▍Free cash flow −71,5% YoY

Operating income -$64.0M.

• ▍Operating income -$64.0M